Windtree Therapeutics Inc

Windtree Therapeutics Inc. a clinical-stage biopharmaceutical company focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF an aerosolized KL4 surfactant which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin a lyophilized KL4 surfactant which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve S.A. for the development marketing and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories Inc. and changed its name to Windtree Therapeutics Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington Pennsylvania.